Skip to content

Released Feb 25, 2022, before the open

10-K filed Feb 25, 2022, 56 days after period end · 0001564590-22-006929

Q4 2021 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$125.06Mderived+6.3% vs Q4 2020+11.2% vs Q3 2021
Net Income-$32.81MderivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$91,810,000+3.7%
Operating Incomederived-$9,353,000N/M
Operating Cash Flowderived$11,779,000−47.2%
Free Cash Flowderived$5,554,000−69.9%
Margins · derived
Gross margin73.4%−1.9 pt vs Q4 2020
Operating margin-7.5%−10.6 pt vs Q4 2020
Net margin-26.2%−18.3 pt vs Q4 2020

What the release said

The release

Same quarter

MetricQ4 2021derived from reported figuresQ4 2020derived from reported figuresQ4 2019Q4 2018
Revenue$125.06M$117.62M$121.49M$121.08M
Net Income-$32.81M-$9.38M$11.69M$8.87M
EPS Diluted——$0.60$0.46

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR